reason report
breath easi cf tri spark pipelin interest
total cystic fibrosi cf product revenu beat
consensu miss forecast vertex beat consensu
estim ep driven strong symdeko
uptak us ou lower expens earli approv
trikafta us along reimburs progress multipl
ou market like boost vertex short-term cf sale
compani commentari suggest tepid free cash flow quarter
grow intern extern spend like persist
previous increas revenu forecast price target follow
trikafta approv reimburs agreement uk
believ current forecast remain larg valid incorpor
current sale trend expens estim beyond
maintain price target reiter market perform rate
stock
cf revenu forecast slightli decreas base rapid
eros exist combin trikafta launch price target
maintain updat revenu expens
forecast base recent quarter commentari total
revenu forecast decreas remain
larg unchang expect faster orkambi convers
ou given current sale trend reduc ou orkambi
forecast forecast cf drug
kalydeco symdeko trikafta larg unchang continu
forecast total revenu grow year
revis forecast consensu base
compani burgeon develop portfolio increas
 forecast year beyond result total
oper expens forecast increas base
chang pro-forma dilut ep estim unchang
reduc compar recent consensu
pro-forma ep revis estim lower
higher addit revis discount
rate multipl reflect latest market condit base
chang maintain price target unchang
reiter market perform rate vrtx stock
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access time
reimburs revenu growth tend later expect market expect
vertex cf revenu grow steadili
consensu expect still robust perform compar consensu
expect believ vertex geograph revenu mix continu heavili weight
us due continu resist payer europ dynam
put current consensu medium-term revenu estim risk probabl success
tripl combin market valuat account full expect
valu cf portfolio well risk-adjust opportun compani effort alpha-
antitrypsin defici aatd even posit view new dcf valuat
incorpor sustain oper margin requir consider
disciplin compani reput frugal
incorpor premium price target recogn vertex might one
attract larg cap growth asset sector howev view reason
acquisit premium would price compani nearli like difficult pill
swallow dilution-avers larg compani
moder revenu driven strong symdeko uptak cf franchis grow strongli
triplet launch doublet convers broader reimburs
vertex total cf product revenu beat consensu miss
forecast global symdeko sale ahead estim
ahead consensu grow sequenti orkambi growth slow
declin qoq howev expect orkambi symdeko grow ou market
trikafta approv reimburs major european countri manag
expect high treatment penetr rate reimburs avail base
experi doublet combin
launch trikafta contribut cf revenu growth us manag expect
high treatment penetr rel rapid convers rate drug said
compani correctli identifi clinic capac like rate limit determin
trajectori launch given lack competit pressur vertex may
interest secur treatment untreat het-min cohort rather convert
exist patient although undoubtedli happen time compani previous
rais cf sale guidanc reiter earn call
view sale trikafta highli achiev though limit
capac cf center might slow uptak
higher revenu lower oper expens drive ep oper margin
continu improv expect low-mid year end
gross margin flat vs estim consensu vertex non-gaap total oper
expens consensu forecast non-gaap
expens consensu estim non-gaap
sg flat vs consensu estim although expens particular
like grow substanti manag expect revenu growth outpac
expens growth result oper margin improv time compani tax rate
line estim slightli higher consensu non-gaap
dilut ep easili beat consensu estim
guidanc reiter follow upward revis last week
vertex reiter full year product revenu guidanc increas
last week follow trikafta approv prior estim
higher consensu non-gaap sg expens guidanc
prior estim bracket consensu non-gaap tax rate
guidanc unchang compani note major compani tax provis
non-cash expens nol fulli deplet
increas support acquisit continu focu diversif
call vertex manag provid extens commentari earli stage clinic
pipelin asset vertex antitrypsin pipelin serv focal point analyst
manag commentari compani explain advanc two oral
small molecul corrector instead gener compound
phase studi expect begin quarter clinic data avail
compani longer suggest one month phase ii trial could pivot continu
defend select biomark endpoint ultim basi futur phase trial
approv compani also expect complet phase studi small
molecul inhibitor function healthi volunt quarter preclin data
suggest could reduc proteinuria patient focal segment glomerulosclerosi
fsg homozyg mutat molecul advanc clinic
rapidli manag believ phase proof-of-concept studi could occur earli
pend success outcom recent initi phase studi
three gene edit program pipelin exon dmd recent
acquir compani semma type diabet vertex tri diversifi away heavi
relianc cf manag indic continu look earli stage asset
add valu well technolog bolt onto gene edit strategi
howev remain skeptic compani competit advantag new
technolog diseas area find vertex argument favor
invest potenti unconvinc link
near-term revenu forecast rais previous reflect triplet earli approv
england reimburs agreement long-term outlook remain larg unchang
previous rais cf forecast follow posit news announc compani last
week link link vertex near-term cf revenu forecast certainli look much
posit believ fundament valuat compani cf franchis remain larg
unchang view compani ou reimburs environ remain challeng
despit recent progress multipl ou market includ england reimburs
pathway tripl still unclear major ou market except germani
assum reimburs upon ema approv base approv histori vertex drug
nh uk spent month reach decis reimburs approv
given larg size address cf patient popul uk
patient nh like take prolong time reach decis reimburs
addit see price anoth neg factor could significantli affect prospect
vertex tripl sale eu particularli uk franc current assum uk
pay doublet price like appli triplet
well current model alreadi assum potenti risk faster
reimburs approv uk favor price agreement offer addit upsid
ou forecast
cf revenu forecast slightli decreas base faster orkambi convers ou
price target remain
updat revenu expens forecast base recent quarter
commentari total revenu forecast decreas remain
larg unchang expect faster orkambi convers ou given current
sale trend reduc ou orkambi forecast forecast
cf drug kalydeco symdeko trikafta remain larg unchang continu
forecast total revenu grow year revis forecast
consensu base compani burgeon develop
portfolio increas forecast year beyond result
total oper expens forecast increas base chang
pro-forma dilut ep estim unchang reduc
compar recent consensu pro-forma ep estim higher lower
higher addit revis discount rate
multipl reflect latest market condit base chang keep price
target unchang reiter market perform rate vrtx stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim
discount back year compani cost equiti give valu one year
use averag mid larg cap biotech price-to-revenu multipl sale
appli revenu estim
post-tripl discount back year compani cost equiti give valu
one year lastli dcf valuat given wacc termin cash flow
growth rate give present valu averag three method
current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
symdeko/symkevi compani main product today materi delay approv
reimburs adopt compani breakthrough new tripl combin medicin
trikafta final compani histori spend much potenti earn
expens diversifi acquisit could undermin futur expect valu compani
cf portfolio opportun better-than expect perform includ realiz signific
revenu compani current cf dual combin market outsid us well
acceler reimburs adopt tripl combin regimen
brand
type event
event trial detail
date known
up/down
expect
first clinic data phase studi
report clinic data peopl two
mutat
evalu abil reduc protein
level urin
svb leerink llc research compani file
million
product sale po adjust
trikafta tripl comb ivacaftor tezacaftor elexacaftor approv
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal earn
current averag growth larg cap biopharma multipl ep nvo
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
